Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 10274
Date Received: 26/06/2025
Summary:
1. Do you currently use Insourcing providers to support delivery of clinical services and reduce patient waiting lists? (Yes/No) 2. If yes, please provide the names of all Insourcing providers used by your Trust over the last 12 months. 3. For each provider listed above, please confirm: o The specialties in which they have delivered services o The total spend with each provider (for the most recent 12-month period available) 4. What specialties within your Trust currently use Insourcing providers? 5. What procurement route(s) did you use to award Insourcing contracts? (e.g. NHS SBS, HealthTrust Europe, local procurement, etc.) 6. Are these contracts part of a framework or spot-purchased? (Please specify for each provider if possible.) 7. What is the duration of the current Insourcing contracts? (Start and end dates, and whether there are extension options.)
Date of Response: 16/07/2025
View Response: 10274.pdf
Freedom of Information Request Reference: 10273
Date Received: 26/06/2025
Summary:
1. Please provide for the NHS Board: a. the current number of accredited trade union representatives for each health trade union specifying the number who are stewards, health and safety reps and learning reps. b. the current number of i) stewards ii) health and safety reps and iii) learning reps for each health trade union who have facility time. c. the current whole time equivalent (WTE) of facility time for each trade union for i) stewards ii) health and safety reps and iii) learning reps d. for each health trade union, the current total headcount number in rep roles, the total number with facility time, and the current whole time equivalent (WTE) of facility time. Please de-duplicate the totals to reflect that some staff hold more than one role. 2. Please provide anonymised for each steward from each health trade union, the current per week of a) total facility time hours b) facility hours allocated to partnership role and c) facility hours allocated to case work. 3. Please provide anonymised for each health and safety rep from each health trade union the current per week of a) total facility time hours b) facility hours allocated to partnership role and c) facility hours allocated to case work. A sample table is provided below to assist with providing this information. 4. Please provide anonymised for each learning rep from each health trade union the current per week of a) total facility time hours b) facility hours allocated to partnership role and c) facility hours allocated to case work. A sample table is provided below to assist with providing this information. 5. Please provide the following total figures for each health trade union for facility time for trade union representatives: a. the total number of hours per week b. the average number of hours per week
Date of Response: 15/07/2025
View Response: 10273.pdf
Freedom of Information Request Reference: 10272
Date Received: 26/06/2025
Summary:
1. A complete list of all GP practices currently operating under NHS Lothian. 2. For each practice, please include the name, address, and the electronic patient record (EPR) system currently in use (e.g. EMIS PCS, Vision (INPS), or any other).
Date of Response: 16/07/2025
View Response: 10272.pdf
Freedom of Information Request Reference: 10271
Date Received: 25/06/2025
Summary:
In the period 1st January-31st March 2024: In the period 1st April-30th June 2024: In the period 1st July - 30th September 2024: In the period 1st October -31st December 2024: 1. What percentage of prostate cancer patients met the 62-day treatment standard? 2. Of all prostate cancer patients in this period, what was the median waiting time from referral to treatment? 3. Of all prostate cancer patients in this period, what was the longest time a patient waited from referral to treatment? 4. How many consultant urologists were employed by the health board? 5. How many unfilled vacancies did the health board have for consultant urologists?
Date of Response: 16/07/2025
View Response: 10271.pdf
Freedom of Information Request Reference: 10270
Date Received: 26/06/2025
Summary:
Please provide the following information you have pertaining to NHS insourcing within your Trust / Health Board. 1. Do you use insourcing providers? 2. If yes to the previous question (use of insourcing providers) what is the total value of spend, listed by speciality and insourcing provider, used for Apr-24-Mar-25? 3. Please list below contracts with insourcing providers in the current financial year Apr-25-Mar-26 Specialty (e.g. general surgery, ophthalmology etc) Insourcing provider Contract start date Contract end date Formal tender process conducted? Procurement framework used for award Estimated contract value
Date of Response: 17/07/2025
View Response: 10270.pdf
Freedom of Information Request Reference: 10267
Date Received: 24/06/2025
Summary:
Could you: •Confirm if your health board has a policy in place across all custody centres within your health board area for maintaining opioid replacement therapy (ORT) for detainees whilst in custody and share this policy with me if possible? •Confirm if all detainees in custody centres within your health board area that receive prescribed methadone are provided with this or if there are timescales attached that mean detainees are not provided with their prescribed methadone, for example only detainees in custody for 48 hours or more continue on ORT while in custody? •If dihydrocodeine is prescribed in any of your custody centres and the circumstances in which this will be prescribed? •If your health board has a controlled drugs licence, covering all custody centres in your area, to facilitate the storing of controlled drugs on site?
Date of Response: 16/07/2025
View Response: 10267.pdf
Freedom of Information Request Reference: 10266
Date Received: 24/06/2025
Summary:
Could I please request infection rates by hospital for orthopaedics and colorectal surgery and could I have the SSI and HAI rates for the hospitals?
Date of Response: 17/07/2025
View Response: 10266.pdf
Freedom of Information Request Reference: 10265
Date Received: 24/06/2025
Summary:
1. In 2024-25 and 2025-26 to date, what is the longest and average waiting times for the follow transplants: a. Kidney b. Liver c. Heart d. Lung e. Pancreas
Date of Response: 15/07/2025
View Response: 10265.pdf
Freedom of Information Request Reference: 10264
Date Received: 24/06/2025
Summary:
I am writing to request information under the Freedom of Information regarding this NHS body and its airborne transmission/masking protocols. 1. How does this NHS body evaluate which medical mask (PPE) is best to use in a given healthcare setting? Please provide any notes or decisions, literature reviews (including their rationale) with regards to this. 2. Please outline your current protocol for staff if and/or when a patient in hospital contracts Covid-19 while receiving healthcare while in an NHS hospital. 3. In total, how many hospital admissions for covid-19 have there been (or how many have been recorded during this timeframe that have been recorded) from the 24th of June 2024 to present date, 24th of June 2025.
Date of Response: 16/07/2025
View Response: 10264.pdf
Freedom of Information Request Reference: 10263
Date Received: 23/06/2025
Summary:
I wish to make a Freedom of Information Request for the cost in 2020, 2021, 2022, 2023, 2024 & 2025 to the present date of the amount spent on Hotels & B&Bs for overnight accommodation for patients, with a breakdown of each year.
Date of Response: 11/07/2025
View Response: 10263.pdf
Freedom of Information Request Reference: 10262
Date Received: 23/06/2025
Summary:
I request the following information for the period January 2019 to March 2025: A list of all contracts and procurement agreements awarded to Circle Health Group Ltd and any of its subsidiaries (including but not limited to Circle Clinical Services Ltd, Circle Health 1 Ltd, Circle Health 2 Ltd, Circle Health 3 Ltd, Circle Health 4 Ltd), including contract value, start and end dates, and a description of the services provided. Copies of board or executive meeting minutes, reports, or briefing notes where decisions regarding contracts with Circle Health Group or its subsidiaries were discussed or approved. The current Register of Interests for all NHS Lothian board members and executives, specifying any financial interests, shareholdings, or other relationships with Circle Health Group or its subsidiaries. Records of any meetings, correspondence, or lobbying activities involving NHS Lothian board members, executives, or procurement officers and representatives of Circle Health Group or its subsidiaries.
Date of Response: 10/07/2025
View Response: 10262.pdf
Freedom of Information Request Reference: 10261
Date Received: 23/06/2025
Summary:
1. The number of patients who presented to your Trust between 1 January 2020 and most recent available data up to January 2025 with complications related to aesthetic injectable procedures, such as dermal fillers or botulinum toxin (Botox). 2. Where available, please provide a breakdown of: – The types of complications (e.g. infection, necrosis, vascular compromise) – The departments involved in managing the cases (e.g. A&E, Plastic Surgery, ENT) – Any cost or coding data available (e.g. HRG codes) for these episodes
Date of Response: 11/07/2025
View Response: 10261.pdf
Freedom of Information Request Reference: 10260
Date Received: 20/06/2025
Summary:
For each calendar year from 2019 through the latest available full year (and, if possible, interim data for 2025): • The number of patient deaths attributed to sepsis.
Date of Response: 10/07/2025
View Response: 10260.pdf
Freedom of Information Request Reference: 10259
Date Received: 20/06/2025
Summary:
Please provide the following figures for financial years 2021/22, 2022/23, 2023/24, 2024/25, and 2025/26 to date – broken down by financial year: 1. Number of instances where psychiatric in-patients were placed in, or transferred to, an inpatient psychiatric hospital, ward, unit, or other similar inpatient psychiatric institution outside of area – for example to another NHS trust, or to a private hospital outside of area. 2. A breakdown of the areas they were sent to, and how many were sent to each area. Please use which ever category you have available to identify the area. 3. Please also provide a breakdown of the reasons for transfer to another location – e.g not enough beds in your NHS trust, specialist care unavailable in your NHS trust etc.
Date of Response: 14/07/2025
View Response: 10259.pdf
Freedom of Information Request Reference: 10258
Date Received: 20/06/2025
Summary:
Please confirm: 1. Has NHS Lothian reviewed or updated any of the following since the ruling: •Equality, Diversity and Inclusion (EDI) policies •Clinical guidance regarding access to sex-segregated care or facilities •HR documents, staff training materials, or legal compliance resources •Safeguarding or patient intake frameworks involving sex-based rights 2. If updates have been made: •Please provide summaries or copies of the revised documents •Include dates and any legal or procedural rationale used in implementing the changes 3. If no changes have been made: •Does NHS Lothian acknowledge this Supreme Court judgment as binding for legal and policy purposes? •Are any reviews currently underway, or planned? 4. Has NHS Lothian issued any briefings, memos, or staff instructions regarding the legal distinction between sex and gender identity for equality, privacy, or patient care purposes?
Date of Response: 11/07/2025
View Response: 10258.pdf
Freedom of Information Request Reference: 10257
Date Received: 20/06/2025
Summary:
1. The total operational budget of NHS Lothian in the Financial Years a) 2022/23, b) 2023/24, and c) 2024/25. 2. The total headcount of NHS Lothian in the Financial Years a) 2022/23, b) 2023/24, and c) 2024/25. 3. The total FTE number of staff employed by NHS Lothian in the Financial Years a) 2022/23, b) 2023/24, and c) 2024/25. 4. The FTE number of staff in the Financial Year 2024/25 earning salaries over a) £50,000, b) £80,000 and c) £100,000.
Date of Response: 16/07/2025
View Response: 10257.pdf
Freedom of Information Request Reference: 10255
Date Received: 19/06/2025
Summary:
1. As of 19 June 2025, or the most recent estimate, how many staff members were given permission to work outside Scotland, or who were working outside Scotland with this body’s knowledge? 2. In relation to Q1, in what country were they working in? Please provide as much data as possible for each employee.
Date of Response: 17/07/2025
View Response: 10255.pdf
Freedom of Information Request Reference: 10254
Date Received: 19/06/2025
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage): •Cobimetinib •Dabrafenib •Dabrafenib + Trametinib •Dacarbazine •Denosumab •Encorafenib + Binimetinib •Ipilimumab monotherapy •Ipilimumab + Nivolumab •Nivolumab monotherapy •Nivolumab + Relatlimab •Pembrolizumab •Trametinib •Vemurafenib •Vemurafenib + Cobimetinib •Other active systemic anti-cancer therapy •Palliative care only Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: •Ipilimumab monotherapy •Ipilimumab + Nivolumab •Nivolumab monotherapy •Nivolumab + Relatlimab •Pembrolizumab •Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) •Other active systemic anti-cancer therapy •Palliative care only Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma? •Ipilimumab (monotherapy) •Nivolumab (monotherapy) •Nivolumab AND Ipilimumab (combination) •Nivolumab AND Relatlimab •Pembrolizumab •Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) •Other active systemic anti-cancer therapy *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. Q4. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 14/07/2025
View Response: 10254.pdf
Freedom of Information Request Reference: 10253
Date Received: 19/06/2025
Summary:
I would like to request the following information relating to your organisation’s use of learning technologies and associated services. 1. Current Learning Management System (LMS) a. What Learning Management System (LMS) or e-learning platform(s) does your organisation currently use? b. If Totara or Moodle is in use, please confirm which version is currently implemented. c. What is the LMS primarily used for (e.g. internal staff development, compliance training, onboarding, external learner access, apprenticeship delivery)? 2. Contract and Provider Details a. Who is your current LMS support, hosting, or implementation provider? b. What is the value of your LMS-related contract per annum? c. What is the contract start and end date (including any optional extension periods)? d. Please confirm if the LMS is hosted on-premise, via a private cloud, or through a SaaS model. 3. Procurement and Decision-Making a. What is the name and role of the person responsible for the learning platform and/or digital learning strategy? b. What is the name and role of the commercial contact responsible for LMS procurement or renewals? 4. Planned Changes or Reviews a. Are there any plans to review or replace your LMS in the next 12–24 months? b. Are there any scheduled or anticipated procurement events or tenders related to learning, compliance, or workforce development systems? 5. Integration and Strategic Use a. Is your LMS currently integrated with other internal systems (e.g. HRIS, payroll, CRM)? b. Are there strategic goals linked to digital learning, compliance reporting, or learner engagement which the LMS is expected to support?
Date of Response: 14/07/2025
View Response: 10253.pdf
Freedom of Information Request Reference: 10252
Date Received: 18/06/2025
Summary:
please provide the following for Prisons, broken down by financial year for years 2021-22, 2022-23, 2023-24, 2024-25, 2025-26 to date: 1. Total expenditure on condoms provided to prisons 2. Total number of condoms provided to prisons 3. Total expenditure on lubricants provided to prisons 4. Total amount of lubricant provided to prisons - in MLs, and by unit 5. Total expenditure on dental dams to prisons 6. Total number of dental dams provided to prisons 7. Total expenditure on femidoms provided to prisons 8. Total number of femidoms provided to prisons 9. Total expenditure on sexual health supplies, with a breakdown of the type of supply and the amount spent on each type - provided to prisons
Date of Response: 14/07/2025
View Response: 10252.pdf
Freedom of Information Request Reference: 10251
Date Received: 18/06/2025
Summary:
Skin surgical site antiseptic / disinfectant preparation ( liquid or wipe) prior to incision : whagt does the trust use and volume or spend over the last 12 months
Date of Response: 11/07/2025
View Response: 10251.pdf
Freedom of Information Request Reference: 10250
Date Received: 18/06/2025
Summary:
• How many people have left NHS Lothian CAMHS waiting lists in order to seek private healthcare per year for the last five years? • How many people generally have left NHS Lothian waiting lists to seek private healthcare per year for the last five years?
Date of Response: 10/07/2025
View Response: 10250.pdf
Freedom of Information Request Reference: 10249
Date Received: 18/06/2025
Summary:
The amount spent by the NHS on purchasing condoms and lubricants for prisoners (broken down by the prison they were sent to) in the calendar years 2021, 2022, 2023, 2024 and 2025. The number of condoms and lubricants distributed by the NHS to prisoners (broken down by the prison they were sent to) in the calendar years 2021, 2022, 2023, 2024 and 2025.
Date of Response: 14/07/2025
View Response: 10249.pdf
Freedom of Information Request Reference: 10248
Date Received: 18/06/2025
Summary:
Can you tell me the total amount of deaths where COVID-19 was noted as the sole cause of death within Ferryfield House Hospital from 2020-2024? Please also separate by age category. Can you tell me the total amount of deaths where COVID-19 was noted as the underlying cause of death within Ferryfield House Hospital from 2020-2024? Please also separate by age category. Can you tell me the total amount of deaths from all causes within Ferryfield House Hospital from since when earliest records are available to 2024?
Date of Response: 09/07/2025
View Response: 10248.pdf
Freedom of Information Request Reference: 10247
Date Received: 18/06/2025
Summary:
Does the NHS provide overnight support packages at home for children in your area? If yes, what band of staff provide that support do you use a scoring tool to assess the level of support and what tool do you use?
Date of Response: 16/07/2025
View Response: 10247.pdf
Freedom of Information Request Reference: 10246
Date Received: 18/06/2025
Summary:
1. The total number of operations performed by Dr Gohil in the last 12 months. 2. The job title and role of Dr Gohil at your hospital and health board. 3. A list of previous hospitals or practices where Dr Gohil has been employed as a surgeon (if this information is held). 4. The number of complaints or investigations made against Dr Gohil in the last 5 years, and the outcomes of those (without disclosing any patient-identifiable details). 5. The number of operations performed by Dr Gohil that were classified as unsuccessful or complications in the last 5 years (without identifying individual cases or patients).
Date of Response: 16/07/2025
View Response: 10246.pdf
Freedom of Information Request Reference: 10245
Date Received: 17/06/2025
Summary:
I am writing under the Freedom of Information Act (2000) to enquire about formaldehyde exposure control and compliance with COSHH (2002) legislation in your Trust’s histopathology department. 1. Can the Trust provide evidence that formaldehyde exposure in its histopathology department(s) is kept as low as reasonably practicable, noting that compliance with the WEL is necessary but not sufficient to demonstrate adequate control 2. If the Trust has decided that totally enclosing the handling of formaldehyde is not reasonably practicable in its histopathology department(s), please provide the formal assessment that was used to reach this conclusion 3. If no such formal assessment has taken place, please state this and clarify the reasons why this has not been done 4. If the Trust relies on open systems for formaldehyde handling (e.g. AFOS tables and LEV), please justify how this represents a “high standard of control” with respect to formaldehyde exposure in the Trust’s histopathology department(s) 5. Can the Trust provide evidence of the procedures and processes employed in its histopathology department(s) to maintain compliance with the COSHH Section 7(4)(c) 6. Can the Trust confirm if laboratory employees are expected to undertake duties not directly related to the dissection of human tissue (for example, administrative tasks), in environments exposed to formaldehyde 7. Can the Trust provide evidence that the frequency with which it monitors formaldehyde exposure in its histopathology department(s) is at least as frequent as when any change occurs that may affect exposure 8. Please provide evidence that the Trust has informed its histopathology staff that formaldehyde is a known human carcinogen and provided details regarding the specific malignancies associated therein, and has also provided education regarding the non-cancer-related health effects of formaldehyde exposure 9. Please provide evidence of the procedures and processes in place to provide the results of formaldehyde exposure monitoring to staff, including but not limited to when the work exposure limit is breached 10. Can the Trust provide evidence that its histopathology department(s) are safe and healthy working environments?
Date of Response: 18/07/2025
View Response: 10245.pdf
Freedom of Information Request Reference: 10244
Date Received: 17/06/2025
Summary:
1. The total number of complaints received by the Portering Department in each of the last four years. 2. A breakdown of complaints by category (e.g., service issues, staff conduct, operational concerns) if such categorisation exists. 3. Any summary reports or analyses conducted regarding these complaints over the requested period. 4. The outcome of complaints, including any actions taken in response (where applicable and anonymised to protect personal data).
Date of Response: 15/07/2025
View Response: 10244.pdf
Freedom of Information Request Reference: 10243
Date Received: 17/06/2025
Summary:
Request in relation to unauthorised access of medical records.
Date of Response: 18/06/2025
View Response: 10243.pdf
Freedom of Information Request Reference: 10240
Date Received: 17/06/2025
Summary:
In EACH of the last two financial years (up to March 31, 2025) and so far this financial year (April 1, 2024 onwards), how many patients have been discharged from hospital with a diagnosis of codes Y42.3 or Y42.8? Please break the figures down for each year and for each type of drug. For clarity, the codes concerned are: Y42.3 (insulin and oral hypoglycaemic [antidiabetic] drugs) Y42.8 (Other and unspecified hormones and their synthetic substitutes)
Date of Response: 10/07/2025
View Response: 10240.pdf
Freedom of Information Request Reference: 10239
Date Received: 16/06/2025
Summary:
How many transplant patients died of COVID between May 2020 and February 2022 in NHS Lothian?
Date of Response: 14/07/2025
View Response: 10239.pdf
Freedom of Information Request Reference: 10236
Date Received: 16/06/2025
Summary:
1. Are colposcopies being included in the waiting list times Gynaecology - colposcopy, as per NHS Lothian Outpatient Waiting Times? 2. How many colposcopy patients have been seen in the period Jun 2024 to May 2025? 3. What was the waiting time in this period, both routine and urgent (as calculated for the NHS Lothian Outpatient Waiting Times? 4. What is the longest waiting time of any patient currently on the waiting list?
Date of Response: 10/07/2025
View Response: 10236.pdf
Freedom of Information Request Reference: 10234
Date Received: 16/06/2025
Summary:
1. Do any hospitals within your health board provide a thoracoscopy services (rigid and/or semi-rigid)? Please specify which hospital(s). 2. If so, please specify: a. The type(s) of thoracoscopy available if known (rigid and or semi-rigid). b. Please provide the manufacturer and model of the thoracoscopy equipment currently in use. c. The location where these procedures are carried out (e.g., operating theatres, endoscopy unit, procedural room, etc.). d. The department responsible for these procedures. e. The number of thoracoscopy procedures performed annually (if available).
Date of Response: 10/07/2025
View Response: 10234.pdf
Freedom of Information Request Reference: 10233
Date Received: 13/06/2025
Summary:
I am looking into neonatal and paediatric critical care pharmacy staffing levels. Please could you share: 1. For each centre within your health board that provides neonatal care, please answer: a. How many funded neonatal intensive care unit (ICU), neonatal high dependency unit (HDU) and special care baby unit (SCBU) cots are there? b. Does the centre have access to a senior pharmacist practising in neonatology at Agenda for Change (AFC) Band 8a or equivalent as a minimum? c. Does the centre have access to a senior pharmacist with experience in the provision of parenteral nutrition, where necessary? d. Do pharmacists working in neonatal care attend daily multidisciplinary ward rounds? e. How many pharmacists (whole time equivalent) working in neonatal care are active independent prescribers? f. Does the centre have access to medicines via the hospital dispensary 7 days a week, with regular stock top ups in accordance with demand, but no less than once a week? g. Does the centre have 5 day access to an aseptic and CIVA service where this is needed to provide bespoke parenteral nutrition or where there is substantial use of high risk intravenous medications? h. Does the centre provide a five day or seven day neonatal service? If this varies for different beds, please answer the below separately for each service. i. How many clinical pharmacists work in neonatal care (whole time equivalent), and at what AfC band? ii. How many ward-based pharmacy technicians work in the neonatal care (whole time equivalent)? 2. Does your health board have a paediatric critical care unit? For each paediatric critical care unit within your trust, please answer: a. How many funded paediatric level 2 and level 3 critical care beds are in the unit? b. Does the unit have access to a senior pharmacist practising in paediatric critical care, funded at Agenda for Change (AFC) Band 8a or equivalent as a minimum? c. Do pharmacists working in paediatric critical care attend daily multidisciplinary ward rounds? d. How many pharmacists (whole time equivalent) in the unit are active independent prescribers? e. Does the unit have access to medicines via the hospital dispensary 7 days a week, with regular stock top ups in accordance with demand, but no less than once a week? f. Does the unit provide a five day or seven day service? If this varies for different beds, please answer the below separately for each service. i. How many clinical pharmacists work in paediatric critical care (whole time equivalent), and at what AfC band? ii. How many ward-based pharmacy technicians work in the unit (whole time equivalent)?
Date of Response: 09/07/2025
View Response: 10233.pdf
Freedom of Information Request Reference: 10232
Date Received: 13/06/2025
Summary:
Please can I request the following information: 1. Is venison served in meals for patients in your health board? 2. How many hospitals has venison been served in meals for patients in your health board across the last five years (please can you break that data up across the last five years)? 3. How much venison, in kilograms, was included in patient meals across the last five years in your health board (if possible, please could you provide that data broken up across the last five years)? 4. How much venison, per meal, was included in patient meals across the last five years in your health board (please could you provide that data broken up across the last five years)?
Date of Response: 09/07/2025
View Response: 10232.pdf
Freedom of Information Request Reference: 10231
Date Received: 13/06/2025
Summary:
Please provide the following information: 1. Engagement Appointments a. Does your health board currently deliver engagement appointments as defined in the CAMHS National Service Specification (2020)? b. If yes, since what date have these appointments been in operation? c. If no, did your board previously deliver engagement appointments? If so, during what period were they delivered? 2. Waiting List Data for Mental Health Disorders a. As of the most recent available date, what is the number of children and young people currently on your internal waiting list for mental health disorders (excluding neurodevelopmental pathways)? b. What is the longest current wait time (in weeks) for a child or young person on: o the internal waiting list for mental health disorders (excluding neurodevelopmental pathways)? o the external waiting list for mental health disorders (excluding neurodevelopmental pathways)?
Date of Response: 10/07/2025
View Response: 10231.pdf
Freedom of Information Request Reference: 10230
Date Received: 12/06/2025
Summary:
What was the organisation's total pay bill for all staff, for financial years 2023/24 and 2024/25?
Date of Response: 10/07/2025
View Response: 10230.pdf
Freedom of Information Request Reference: 10229
Date Received: 12/06/2025
Summary:
I would therefore ask NHS Lothian to: 1. Reissue the response in an accessible format e.g., a single document in plain English 2. Provide all withheld information e.g., training materials, audit reports or properly justify exemptions under FOISA. 3. Confirm compliance with the Equality Act 2010 and Accessibility Regulations 2018 in future FOI responses.
Date of Response: 10/07/2025
View Response: 10229.pdf
Freedom of Information Request Reference: 10228
Date Received: 12/06/2025
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) : •Avelumab + Axitinib •Axinitib •Cabozantinib •Everolimus •Lenvatinib + Everolimus •Lenvatinib + Pembrolizumab •Nivolumab monotherapy •Nivolumab + Cabozantinib •Nivolumab + Ipilimumab •Pazopanib •Pembrolizumab monotherapy •Pembrolizumab + Axitinib •Radiotherapy only •Sunitinib •Temsirolimus •Tivozanib •Other active systemic anti-cancer therapy •Palliative care only Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments: •Avelumab + Axitinib (Bavencio + Inlyta) •Cabozantinib (Cometriq) •Nivolumab (Opdivo) •Nivolumab + Cabozantinib (Opdivo + Cometriq) •Nivolumab + Ipilimumab (Opdivo + Yervoy) •Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? •Nivolumab (monotherapy) •Nivolumab + Ipilimumab •Nivolumab + Cabozantinib •Avelumab + Axitinib •Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)? Q5. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?
Date of Response: 09/07/2025
View Response: 10228.pdf
Freedom of Information Request Reference: 10227
Date Received: 12/06/2025
Summary:
I would like to request some information on the ultrasonic aspiration devices currently in use in operating theatres within LOTHIAN HB please. Specifically: • Name of Hospital • Number of Sonopet units (brand/supplier is Stryker Ltd) currently in use and dates of manufacture/installation for each • Number of CUSA units (brand/supplier is INTEGRA NEUROSCIENCES LTD) currently in use and dates of manufacture/installation for each • Total number of Sonopet disposables used in 2024 • Total number of CUSA disposables used in 2024 • Are these disposables procured through the NHS Supply Chain framework or are they ordered directly from the supplier?
Date of Response: 04/07/2025
View Response: 10227.pdf
Freedom of Information Request Reference: 10226
Date Received: 12/06/2025
Summary:
For the 4 months from January to April 2025, how many unique* patients received the following intra-vitreal treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab
Date of Response: 04/07/2025
View Response: 10226.pdf
Freedom of Information Request Reference: 10224
Date Received: 11/06/2025
Summary:
1. Contract Register Please provide a complete and current extract of your organisation’s contract register or equivalent database. We are not asking you to compile new information or manually populate missing fields – we simply request the register in its existing form, preferably in Excel or CSV format. Where available, we are particularly interested in the following fields (though this is not a strict requirement): • Contract Title • Supplier Name • Estimated Spend (Total or Annual) • Contract Duration and Total Period (including extensions) • Contract Start and Expiry Dates • Review Date • Contract Description • Contract Owner (Name, Job Title, Contact Details if available) • Contract Notes • Managing Department • Award Date • Participating Organisations • Procurement Category • Framework or Tender References • Central Purchasing Body • Classification Codes (CPV, Pro-Class, etc.) Please don’t spend time populating these fields if they aren’t readily available – we welcome receiving the raw register as it exists in your system. 2. Total Number of Active Contracts Please confirm the total number of contracts currently listed as active. 3. Procurement Strategy (2025/2026) Please provide your organisation’s Procurement Strategy for 2025/2026. • If this is part of a multi-year strategy (e.g., 2024–2028), please provide the most recent version covering 2025/2026 or indicate when this will be available. • If any parts are redacted, please identify the redacted sections and the reason. 4. Contact Information If possible, please provide the name, job title, phone number, and email address for the following roles: • Responsible officer for API access or data sharing (if applicable) • Individual managing the contract register • Finance Director • Head/Director of Procurement or Purchasing • Head/Director of ICT • Head of Estates and Facilities • Relevant Committee Member, Councillor, or Board Member for Procurement/Finance If direct contact details are restricted due to GDPR, please indicate the best department or method of contact. 5. Additional Notes • If your contract register is available via an online portal, please ensure all records are accessible (as some portals may only show summary data). • If your organisation uses a contract management system or CRM, please confirm whether it allows for data exports. • If you intend to withhold spend figures, please note that we are requesting an overall total or indicative spend only – not a line-by-line financial breakdown.
Date of Response: 08/07/2025
View Response: 10224.pdf
Freedom of Information Request Reference: 10223
Date Received: 11/06/2025
Summary:
May I request the following information under freedom of information legislation: 1. The total amount of money spent on consultants by your organisation in 2021-22, 2022-23, 2023-24 and 2024-25. 2. The total amount of money spent on agency staff by your organisation in 2021-22, 2022-23, 2023-24 and 2024-25. 3. The total amount of money spent on recruitment agencies by your organisation in 2021-22, 2022-23, 2023-24 and 2024-25.
Date of Response: 09/07/2025
View Response: 10223.pdf
Freedom of Information Request Reference: 10222
Date Received: 11/06/2025
Summary:
1. Wound Care Data Collection • Does your ICB collect or receive data on wound care, particularly for chronic wounds (e.g. leg ulcers, pressure ulcers, diabetic foot ulcers)? • If not, are there plans to do so within the next 12months? • What specific data points are collected (e.g. wound type, healing time, product usage, care setting, clinical outcomes)? • How is this data collected (e.g. electronic patient records, community health systems, audits)? • Is data collection standardised across providers within your ICB footprint? 2. Data Usage and Sharing • For what purposes is wound care data used (e.g. commissioning, performance management, service planning)? • Is this data shared outside your organisation (e.g. NHS England, research bodies, suppliers)? If yes, under what governance or agreements? 3. Technology and Digital Systems • What digital systems or platforms are currently used for recording and managing wound care data (e.g. EMIS, SystmOne, bespoke solutions)? • Are there any current or upcoming digital transformation initiatives focused on wound care? 4. Spend and Commissioning • Does your ICB hold data on spend related to wound care (e.g. dressings, devices, service delivery)? • Are wound care services commissioned centrally by the ICB or delegated to Place or provider level?
Date of Response: 17/07/2025
View Response: 10222.pdf
Freedom of Information Request Reference: 10220
Date Received: 11/06/2025
Summary:
I am seeking footage from the CCTV cameras covering the third floor of the Alexander Donald building at the Western General Hospital for the period of 5 January 2025, between 2:00 PM and 7:00 PM.
Date of Response: 04/07/2025
View Response: 10220.pdf
Freedom of Information Request Reference: 10219
Date Received: 10/06/2025
Summary:
I wish to obtain: 1. CCTV Footage: - Recordings from disabled car parking spaces behind D block (near the blue car park booth, between car park six and seven the time period 06/01/25 0800-1600. - Any available footage in an electronic format (e.g., digital file, DVD) would be preferred. 2. Body Camera Footage: - Recordings captured by body cameras during for the period 06/01/25 1100 - 1400 between car park six and seven. - I understand that if any of the requested footage includes identifiable personal data or sensitive information, applicable exemptions under data protection legislation may need to be applied. If so, I would appreciate an explanation of the exemptions used as well as any non-exempt or redacted footage available.
Date of Response: 04/07/2025
View Response: 10219.pdf
Freedom of Information Request Reference: 10218
Date Received: 10/06/2025
Summary:
I am writing under the Freedom of Information (Scotland) Act 2002 to request records held by Western General Hospital concerning an allegation that an individual has continuously parked in a disabled parking space for approximately 10 years. It has come to my attention that the individual’s details have been recorded anonymously. Specifically, I request the following: 1. Identification Records: Any records or documentation that identify the individual concerned (e.g., name, vehicle registration number, or other identifying details), subject to disclosure. If the personal data is exempt in full or in part under data protection legislation, please provide an explanation and any available anonymized or non-personal data. 2. Background Documentation: Any internal investigation notes, reports, or correspondence relating to this alleged long-term parking in a disabled spot, including details on how the case was processed and any actions that were taken. 3. Policy Information: Documentation outlining the hospital's policies and procedures concerning disabled parking spaces and how repeated or prolonged misuse is recorded and managed.
Date of Response: 04/07/2025
View Response: 10218.pdf
Freedom of Information Request Reference: 10217
Date Received: 10/06/2025
Summary:
I would like to request any recorded information held by the western general hospital pertaining to the criteria, policies, and procedural documentation concerning the determination of car parking ineligibility. In particular, I am interested in: - Any internal documents, memos, or records that detail the criteria used to classify vehicles or individuals as ineligible for parking. - Records outlining any decisions, appeals, or discussions regarding parking eligibility. - Documentation covering the period between 01/04/24 and 09/06/25].
Date of Response: 04/07/2025
View Response: 10217.pdf
Freedom of Information Request Reference: 10216
Date Received: 10/06/2025
Summary:
Can I request the following information for the time period covering from the calendar year from 2021 to 2025 (most recent): 1. The longest time period (in days) in between sending out appointment letters for breast screening to any region/location?
Date of Response: 04/07/2025
View Response: 10216.pdf
Freedom of Information Request Reference: 10215
Date Received: 10/06/2025
Summary:
A. How many patients have been treated with the following drugs in the past 4 months: •Atogepant (Aquipta) – any disease •Erenumab (Aimovig) - any disease •Eptinezumab (Vyepti) – any disease •Fremanezumab (Ajovy) - any disease •Galcanezumab (Emgality) - any disease •Rimegepant (Vydura) – any disease •Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY B. How many patients have you treated in the last 4 months for acute migraine with: •Rimegepant (Vydura) C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?
Date of Response: 10/07/2025
View Response: 10215.pdf
Freedom of Information Request Reference: 10214
Date Received: 09/06/2025
Summary:
I am writing to kindly request the most up-to-date total number of orthopaedic procedures carried out within NHS Lothian. If possible, could this data also include a breakdown by individual consultant/surgeon? I would be grateful if you could advise on the available data and whether it can be shared, either in summary form or at an anonymised consultant level if needed.
Date of Response: 04/07/2025
View Response: 10214.pdf
Freedom of Information Request Reference: 10213
Date Received: 09/06/2025
Summary:
1) The Health Boards guidelines for prescribing medication for Urinary Tract Infections. 2) The number of patients in 2024/2025 prescribed Trimethoprim for Urinary Tract Infections. 3) The number of patients who had to subsequently been prescribed an alternative medication after Trimethoprim was unsuccessful in curing thier Urinary Tract Infection.
Date of Response: 04/07/2025
View Response: 10213.pdf
Freedom of Information Request Reference: 10212
Date Received: 09/06/2025
Summary:
Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) •Amivantamab •Atezolizumab Monotherapy •Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel •Atezolizumab subcutaneous •Dabrafenib + Trametinib •Docetaxel monotherapy or in combination with Carboplatin/Cisplatin •Durvalumab •Gemcitabine •Nintedanib + Docetaxel •Nivolumab •Osimertinib •Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) •Paclitaxel •Pembrolizumab Monotherapy •Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) •Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) •Pemetrexed + Platinum (Carboplatin/Cisplatin) •RET Inhibitors (Pralsetinib, Selpercatinib) •Sotorasib •Tepotinib •Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin •Other active systemic anti-cancer therapy •Palliative care only •Amivantamab with carboplatin and pemetrexed •Cemiplimab with platinum-based chemotherapy Q2. Does your trust participate in any Clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 04/07/2025
View Response: 10212.pdf
Freedom of Information Request Reference: 10211
Date Received: 09/06/2025
Summary:
Could you please provide the current - and, if different, historic to circa twenty years - schedule of routine replacemnt of patient monitors in your NHS facilities.
Date of Response: 04/07/2025
View Response: 10211.pdf
Freedom of Information Request Reference: 10210
Date Received: 09/06/2025
Summary:
Can I ask that this decision be formally reviewed please, given that I know the information on the number of patients who were left with a spinal cord injury following both the open and endoivacular procdures is wrong.
Date of Response: 07/07/2025
View Response: 10210.pdf
Freedom of Information Request Reference: 10209
Date Received: 09/06/2025
Summary:
I would like to request information regarding your current and planned usage of solar energy across your estate. Please could you provide responses to the following questions: 1. Governance & Responsibility o Do you have a dedicated person or team responsible for solar energy investment and/or sustainability energy initiatives within your organisation? o If so, please provide their role/title (personal names are not required). 2. Current Solar Deployment o How many solar panel installations (PV systems) do you currently operate across your estate? o What is the total installed capacity of these systems (in kWp)? o What proportion of your organisation’s energy usage is currently provided by solar generation? 3. Investment & Strategy o Does your organisation have a documented investment strategy for expanding the use of solar panels or increasing on-site renewable energy generation? o If so, please provide a copy of or link to the relevant strategy or plan (or summarise key points if not published). 4. Solar and Net Zero Commitments o Does solar energy form part of your organisation’s Net Zero / Carbon Reduction Strategy? o If yes, how is progress against this strategy communicated to the public (e.g. via website, reports, dashboards, etc.)? 5. Future Plans o Are there any planned solar panel projects or expansions within the next 3 years? If yes, please provide high-level details (e.g. number of sites, scale of deployment, approximate timescales). o Have you conducted any feasibility studies on increasing solar capacity in the past 3 years? If so, can these be shared? 6. Procurement & Partnerships o Does your organisation currently use any third-party companies or frameworks to deliver solar energy solutions or manage installations? If yes, which ones? o Are there any upcoming procurement exercises planned relating to solar energy or wider renewable energy solutions? 7. Battery Storage o Do you currently use battery storage alongside your solar panels? o Are there plans to invest in battery storage in future? 8. Funding o Has your organisation accessed or applied for any external funding to support solar energy projects (e.g. SALIX, Public Sector Decarbonisation Scheme, LEP funding)? 9. Barriers o What are the main barriers your organisation faces to further adoption of solar energy (e.g. funding, planning restrictions, roof suitability, internal resource)?
Date of Response: 04/07/2025
View Response: 10209.pdf
Freedom of Information Request Reference: 10208
Date Received: 09/06/2025
Summary:
Please can you provide me with the Agency Spend, split between the 3 individual staff groups below : 1. Agency Registered Nurses (all specialities e.g. adult nursing, children’s nursing, community, mental health, midwives, etc) – April 2025 2. Agency Health Care Support Workers – April 2025 3. Agency Doctors - April 2025
Date of Response: 04/07/2025
View Response: 10208.pdf
Freedom of Information Request Reference: 10207
Date Received: 09/06/2025
Summary:
To ask, in each of the last five years, how many cases have been recorded in your health board area of the disease Rickets? If possible, could this be broken down by approximate age of patient.
Date of Response: 02/07/2025
View Response: 10207.pdf
Freedom of Information Request Reference: 10206
Date Received: 09/06/2025
Summary:
On a previous FOI request, your trust has indicated that you may have a lead for regional anaesthesia. If this statement is correct, please could I put in a further FOI for their name and if possible, their contact details.
Date of Response: 04/07/2025
View Response: 10206.pdf
Freedom of Information Request Reference: 10205
Date Received: 09/06/2025
Summary:
I would like to request the following information regarding Riverside Medical Practice in Musselburgh: 1. The total amount of NHS funding paid to Riverside Medical Practice for the most recent financial year available. 2. The number of GP partners or equivalent managing clinicians operating under the contract with NHS Lothian during that same period. 3. Any available information on how this funding is distributed within the practice, specifically: • Whether GP partners receive a fixed salary or a share of profits. • The total profit declared by the practice (if available) and how this was allocated to partners. 4. Any publicly held or published documentation regarding the remuneration model for GP partners at Riverside Medical Practice (e.g. practice contracts, governance statements).
Date of Response: 15/07/2025
View Response: 10205.pdf
Freedom of Information Request Reference: 10204
Date Received: 06/06/2025
Summary:
How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: •Adalimumab - Humira •Adalimumab Biosimilar •Etrasimod •Filgotinib •Golimumab •Infliximab - Remicade •Infliximab Biosimilar •Mirikizumab •Ozanimod •Risankizumab •Tofacitinib •Upadacitinib •Ustekinumab - Stelara •Ustekinumab Biosimilar •Vedolizumab
Date of Response: 04/07/2025
View Response: 10204.pdf
Freedom of Information Request Reference: 10202
Date Received: 06/06/2025
Summary:
Has the health board became accredited with the Equally Safe at Work employer accreditation programme, as outlined in the Women’s Health Plan?
Date of Response: 04/07/2025
View Response: 10202.pdf
Freedom of Information Request Reference: 10037
Date Received: 28/04/2025
Summary:
How many surgeons do you currently employ in your regional board that specifically operate on women suffering from endometriosis? How many of these surgeons work 5 days a week for your regional board? How many endometriosis surgeries have you performed annually over the past 5 years? What are your current estimated wait times for surgery to alleviate symptoms of endometriosis and how many women are currently on your wait list?
Date of Response: 18/07/2025
View Response: 10037.pdf
Freedom of Information Request Reference: 10200
Date Received: 06/06/2025
Summary:
1. Is your health board currently treating myeloma patients 2. Please list the hospitals in your board that are currently treating myeloma patients. 3. Please list how many myeloma patients are being treated a) by your health board b) broken down by hospital 4. Is your health board currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital. 5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the Scottish Medicines Consortium in 2024 (SMC2669 and SMC2668) If possible, please break this down by hospital. 6. Do you have a service level agreement or referral system in place with any other health boards to deliver a) elranatamab or b) teclistamab to patients. If the answer to question this is yes, which health boards do you have an agreement in place with.
Date of Response: 08/07/2025
View Response: 10200.pdf
Freedom of Information Request Reference: 10199
Date Received: 06/06/2025
Summary:
1. The total number of attendances to A&E departments within this NHS health board who have reported that they have sustained an injury related to a seagull. (Please could you break this up by the last three years, 2022-23, 2023-24 and 2024-25). 2. The severity of the injuries recorded in (1).
Date of Response: 04/07/2025
View Response: 10199.pdf
Freedom of Information Request Reference: 10198
Date Received: 05/06/2025
Summary:
Under the Freedom of Information Act, can you please supply for your NHS board: ● The total number of consultant-level doctors you currently have [WTE or equivalent] ● The total number of vacant consultant-level doctor posts you currently have [WTE or equivalent] Please also supply: ● The total number of consultant-level posts substantially filled by agency locums for more than 6 months [WTE or equivalent] ● The total spend on agencies for locum consultants (both framework and non-framework) for the 2024/25 financial year [£s] ● Any existing or planned controls on recruitment of medical staff in 2025/26 [free text]
Date of Response: 03/07/2025
View Response: 10198.pdf
Freedom of Information Request Reference: 10197
Date Received: 05/06/2025
Summary:
I wish to make a FOISA request for the following information for you Out of Hours Service only. All questions relate to years 22/23, 23/24 and 24/25 What was the allocated OOH Budget for each year? What was the OOH spend for year year? How many salaried/sessional/bank staff do you have for all staff groups? What is each budget for all staff groups for each year? What is the spend for all staff groups for each year?
Date of Response: 03/07/2025
View Response: 10197.pdf
Freedom of Information Request Reference: 10196
Date Received: 05/06/2025
Summary:
In the last 6 months, please confirm if any Mental Health services have been outsourced: If yes, please confirm: -The service provided E.G ADHD, Autism etc (please provide breakdown for each service if applicable) -The name of the company each service was outsourced to -Is there a contract in place and the length of contract for each service provided (if applicable) -The value of each service in the last 6 months Please provide an email and contact name within the outsource provider
Date of Response: 03/07/2025
View Response: 10196.pdf
Freedom of Information Request Reference: 10195
Date Received: 05/06/2025
Summary:
Would like to request the following information for NHs Lothian · Octenisan Wash Lotion 150ml : latest 12 months available · Octenisan Wash Lotion 500ml : latest 12 months available · Octenisan Nasel Gel : latest 12 months available · Octenisan Wash Mitts : latest 12 months available
Date of Response: 30/06/2025
View Response: 10195.pdf
Freedom of Information Request Reference: 10193
Date Received: 04/06/2025
Summary:
1. From 1st March 2025 to 31st May 2025, please list the wards/departments you have requested shifts for off framework agencies in your Adult Nursing, Mental Health, Community Teams? 2. Please provide a list of off-framework agencies used by the Trust from 1st March 2025 to 31st May 2025 and the amount of off framework spend for each agency. 3. How much was your Off-Framework agency spend for each of the following staff groups between 1st March 2025 to 31st May 2025 (a) RGN's (b) RCN's (c) RMN (d) ITU Nurse (e) A&E Nurse (f) HCA (g) CPN (h) NICU Nurse 4. Please provide me with the name, contact number & email address of the person responsible for responsible for temporary nursing agency onboarding for your Trust?
Date of Response: 02/07/2025
View Response: 10193.pdf
Freedom of Information Request Reference: 10192
Date Received: 04/06/2025
Summary:
1. Standard Firewall (Network) Firewall services that protect the organisation’s network from unauthorised access and other internet security threats. 2. Anti-virus Software Application Programs designed to prevent, detect, and remove viruses, malware, trojans, adware, and related threats. 3. Microsoft Enterprise Agreement A volume licensing agreement that may include: • Microsoft 365 (Office, Exchange, SharePoint, Teams) • Windows Enterprise • Enterprise Mobility + Security (EMS) • Azure services (committed or pay-as-you-go) 4. Microsoft Power BI Or any alternative business intelligence platform used for data connectivity, dashboards, and reporting. ________________________________________ For each of the above areas, I kindly request the following: 1. Who is the existing supplier for this contract? 2. What is the annual spend for each contract? 3. What is the description of the services provided? 4. Primary brand (where applicable) 5. What is the start date of the contract? 6. What is the expiry date of the contract? 7. What is the total duration of the contract? 8. Who is the responsible contract officer?  • Please include at least their job title, and where possible, name, contact number, and direct email address 9. How many licences or users are included (where applicable)?
Date of Response: 02/07/2025
View Response: 10192.pdf
Freedom of Information Request Reference: 10191
Date Received: 04/06/2025
Summary:
1) The total amount of money spent by your organisation on overtime payments in 2021-22, 2022-23, 2023-24 and 2024-25 (financial years). 2) The total amount of money spent fixing/replacing broken equipment in 2021-22, 2022-23, 2023-24 and 2024-25 (financial years). 3) The total financial loss to your organisation on written off inventory and IT equipment in 2021-22, 2022-23, 2023-24 and 2024-25 (financial years).
Date of Response: 02/07/2025
View Response: 10191.pdf
Freedom of Information Request Reference: 10190
Date Received: 04/06/2025
Summary:
We would be grateful if you could provide the following information: - How Botulinum Toxin injection clinics in Neurology (excluding migraine) are coded within your Trust (e.g., outpatient follow-up, procedure, day case procedure, etc.). - The current tariff your Trust receives for administering Botulinum Toxin injections in Neurology (excluding migraine). - How Botulinum Toxin injection clinics in Rehabilitation Medicine are coded within your Trust (e.g., outpatient follow-up, procedure, day case procedure, etc.). - The current tariff your Trust receives for administering Botulinum Toxin injections in Rehabilitation Medicine clinics. - Has there been a change in how the trust is commissioning Neurological and Rehabilitation toxins services from April 2025 compared to 2024? - The name and contact details (email or phone number, if available) of the most appropriate person within your Trust to discuss these services further
Date of Response: 10/07/2025
View Response: 10190.pdf
Freedom of Information Request Reference: 10189
Date Received: 04/06/2025
Summary:
Please provide the RIE maternity statistics for March 2024.
Date of Response: 16/06/2025
View Response: 10189.pdf
Freedom of Information Request Reference: 10187
Date Received: 03/06/2025
Summary:
Please can you provide me with any details you can about the number of patients who have presented at or been admitted to hospital in EACH of the last two financial years (up to March 31, 2025) and so far this financial year (April 1, 2024 onwards) for health problems caused by taking any of the following drugs: Wegovy (Semaglutide); Saxenda (Liraglutide); Ozempic (Semaglutide); Mounjaro (Tirzepatide); Victoza (Liraglutide). Please break the figures down for each year and for each type of drug.
Date of Response: 01/07/2025
View Response: 10187.pdf
Freedom of Information Request Reference: 10186
Date Received: 03/06/2025
Summary:
Please provide the following data for financial years 2021-22, 2022-23, 2023-24, 2024-25, and 2025 to date (broken down by financial year): By “in-patient psychiatric unit,” I am referring to all in-patient psychiatric/mental health wards, hospitals, or similar in-patient mental health/psychiatric institutions. 1. The mean average staff to patient ratio in in-patient psychiatric units 2. The mean average doctor to patient ratio in in-patient psychiatric units 3. The mean average nurse to patient ratio in in-patient psychiatric units 4. The mean average healthcare professional to patient ratio in in-patient psychiatric units 5. The mode average staff to patient ratio in in-patient psychiatric units 6. The mode average doctor to patient ratio in in-patient psychiatric units 7. The mode average nurse to patient ratio in in-patient psychiatric units 8. The mode average healthcare professional to patient ratio in in-patient psychiatric units 9. The median average staff to patient ratio in in-patient psychiatric units 10. The median average doctor to patient ratio in in-patient psychiatric units 11. The median average nurse to patient ratio in in-patient psychiatric units 12. The median average healthcare professional to patient ratio in in-patient psychiatric units 13. Please provide any statutory or internal guidelines on the target staff to patient ratios, including targets for all categories of staff.
Date of Response: 17/07/2025
View Response: 10186.pdf
Freedom of Information Request Reference: 10185
Date Received: 03/06/2025
Summary:
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: •Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Abemaciclib + Fulvestrant •Alpelisib + Fulvestrant •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel •Atezolizumab •Capivasertib •Capecitabine as a single agent •Carboplatin + Paclitaxel •Elacestrant •Eribulin as a single agent or in combination •Everolimus + Exemestane •Fulvestrant as a single agent •Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Palbociclib + Fulvestrant •Parp Inhibitors (Olaparib/Talazoparib) •Pembrolizumab Monotherapy •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab •Carboplatin + Paclitaxel + Pembrolizumab •Pertuzumab (Perteja) + Trastuzumab (Herceptin) •Phesgo (Pertuzumab + Trastuzumab in a single injection) •Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Ribociclib + Fulvestrant •Sacituzumab Govitecan •Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent •Trastuzumab deruxtecan (Enhertu) •Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel •Trastuzumab emtansine (Kadcyla) •Any other active systemic anti-cancer therapy •Aromatase Inhibitor as a single agent Q2. How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies: •Phesgo (Pertuzumab + Trastuzumab in a single injection) •Pertuzumab (Perteja) + Trastuzumab (Herceptin) •Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel •Trastuzumab deruxtecan (Enhertu) •Trastuzumab emtansine (Kadcyla) •Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Abemaciclib + Fulvestrant •Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Ribociclib + Fulvestrant •Capecitabine as a single agent •Carboplatin + Paclitaxel •Carboplatin + Paclitaxel + Pembrolizumab Q3. Does your trust participate in any Clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 01/07/2025
View Response: 10185.pdf
Freedom of Information Request Reference: 10184
Date Received: 03/06/2025
Summary:
I request that any data held for presentations to your Trust Emergency Department(s) where the reason for presentation has been due to a chainsaw-related incident. Please could you share data for the last 10 years for all presentations that are associated with use of a chainsaw.
Date of Response: 26/06/2025
View Response: 10184.pdf
Freedom of Information Request Reference: 10183
Date Received: 03/06/2025
Summary:
1. The total annualised staffing cost and number of hours worked (or WTE if unavailable) for medical and dental professionals employed directly by your Board, split by financial year from FY 2015/16 to most recent available. 2. The total annualised staffing cost and number of hours worked (or WTE if unavailable ) for nursing and midwifery professionals employed directly by your Board, split by financial year from FY 2015/16 to most recent available. 3. The total annualised staffing cost and number of hours worked (or WTE if unavailable ) for medical and dental professionals contracted via agency by your Board, split by financial year from FY 2015/16 to most recent available. 4. The total annualised staffing cost and number of hours worked (or WTE if unavailable) for medical and dental professionals contracted via bank by your Board, split by financial year from FY 2015/16 to most recent available. 5. The total annualised staffing cost and number of hours worked (or WTE if unavailable) for nursing and midwifery professionals contracted via agency by your Board, split by financial year from FY 2015/16 to most recent available. 6. The total annualised staffing cost and number of hours worked (or WTE if unavailable) for nursing and midwifery professionals contracted via bank by your Board, split by financial year from FY 2015/16 to most recent available.
Date of Response: 04/07/2025
View Response: 10183.pdf
Freedom of Information Request Reference: 10182
Date Received: 02/06/2025
Summary:
Can I request the following information for each calendar year from 2022 to 2025 (most recent): 1. The median distance (in miles) someone has travel for their Breast Screening appointment. (From their home address to the van location) 2. The longest distance (in miles) someone has travel for their Breast Screening appointment. (From their home address to the van location) 3. The number of vans used for breast screening within your health board.
Date of Response: 27/06/2025
View Response: 10182.pdf
Freedom of Information Request Reference: 10181
Date Received: 02/06/2025
Summary:
1. How many Agency shifts were advertised by this health board in NHS hospitals in 2024-25? Please provide this for each financial year since 2018-19. Please break this down into Nursing and Midwifery, as well as Medical and Dental. 2. In relation to Question 1, how many of these shifts were successfully filled? Please provide this for each financial year since 2018-19, including the current financial year. 3. Please provide the overall spend so far on agency staff in 2024-25. Please provide this for each financial year since 2018-19. Please break this down into Nursing and Midwifery, as well as Medical and Dental. 4. How many Bank shifts were advertised by this health board in NHS hospitals in 2024-25? Please provide this for each financial year since 2018-19. Please break this down into Nursing and Midwifery, as well as Medical and Dental. 5. In relation to Question 4, how many of these shifts were successfully filled? Please provide this for each financial year since 2018-19, including the current financial year. 6. Please provide the overall spend so far on bank staff in 2024-25. Please provide this for each financial year since 2018-19. Please break this down into Nursing and Midwifery, as well as Medical and Dental.
Date of Response: 27/06/2025
View Response: 10181.pdf
Freedom of Information Request Reference: 10180
Date Received: 03/06/2025
Summary:
How many patients over 18 have been referred to health service weight management services in each of the last five years in this region?
Date of Response: 01/07/2025
View Response: 10180.pdf
Freedom of Information Request Reference: 10179
Date Received: 02/06/2025
Summary:
My request is for the number of time, in weeks or any other length of time available, that patients are waiting for a follow-up appointment following a cervical smear test in NHS Lothian.
Date of Response: 30/06/2025
View Response: 10179.pdf
Freedom of Information Request Reference: 10178
Date Received: 02/06/2025
Summary:
1. The number of unique patients with a recorded diagnosis of Dravet syndrome in 2024-2025. Likely coded as ICD-10 code G40.3 or SNOMED code of 230437002, ideally separated by month. a. Patient numbers segmented by age: i. 0-3 years old, ii. 4-8 years old, iii. 9-18 years old, iv. 18 years+ 2. The number of unique patients with a recorded diagnosis of Lennox-Gastaut syndrome in 2024-2025. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006, ideally separated by month. a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ 3. The number of unique patients who have been treated with fenfluramine in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside fenfluramine, and indicate the number of patients receiving each 4. The number of unique patients who have been treated with cannabidiol in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cannabidiol, and indicate the number of patients receiving each 5. The number of unique patients who have been treated with cenobamate in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cenobamate, and indicate the number of patients receiving each 6. The number of unique patients who have been treated with rufinamide in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside rufinamide, and indicate the number of patients receiving each 7. The number of unique patients who have been treated with stiripentol in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside stiripentol, and indicate the number of patients receiving each 8. The number of unique patients who have been treated with clobazam in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside clobazam, and indicate the number of patients receiving each 9. The number of unique patients who have been treated with sodium valproate in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside sodium valproate, and indicate the number of patients receiving each 10. The number of unique patients who have been treated with levetiracetam in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside levetiracetam, and indicate the number of patients receiving each 11. The number of unique patients who have been treated with topiramate in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside topiramate, and indicate the number of patients receiving each 12. The number of unique patients who have been treated with lamotrigine in 2024-2025, separated by month a. Patient numbers segmented by age: i. 0-3 years old ii. 4-8 years old iii. 9-18 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside lamotrigine, and indicate the number of patients receiving each
Date of Response: 30/06/2025
View Response: 10178.pdf
Freedom of Information Request Reference: 10177
Date Received: 02/06/2025
Summary:
Can you confirm for the previous three years broken down by year the number of applications for referral from CAMHS to AMHS. Of that, please confirm the number of applications accepted and the number rejected. Of those rejected, please state which tier of support they had received e.g. tier 3. Can you confirm how many were recorded as not meeting the threshold/criteria for continued support. Of those rejected, how many don't have reasons recorded. Can you also confirm how many young people were retained by CAMHS after turning 18.
Date of Response: 26/06/2025
View Response: 10177.pdf
Freedom of Information Request Reference: 10176
Date Received: 02/06/2025
Summary:
What was the total number of prescriptions issued for off-label use of fibrate medicines in the treatment of patients with a diagnosis of primary biliary cholangitis in each of the past three years?
Date of Response: 24/06/2025
View Response: 10176.pdf
Freedom of Information Request Reference: 10174
Date Received: 30/05/2025
Summary:
In the past 3 years, have any visits to the website 'OnlyFans.com' been recorded on NHS systems or devices (including mobile devices) used by NHS staff and what proportion of these staff were in management positions? I am defining management positions to include operational managers, facilities and estates managers, IT managers, chief executives and directors on the health board and workforce managers (manages staff and other employees). If 3 years is too long, then can I ask for this information for the last calendar year (2024 - 2025) and the first six months of 2025 as of 30 May 2025. If such visits to this site were recorded, please provide: - The number of unique instances where the site was accessed. - The dates and times (if available) when these accesses occurred. - Whether the accesses were made during working hours. - Whether these visits were flagged or investigated by IT or security teams.
Date of Response: 25/06/2025
View Response: 10174.pdf
Freedom of Information Request Reference: 10173
Date Received: 30/05/2025
Summary:
Can I request the following information for each calendar year from 2019 to 2025 (most recent): 1. The median completed wait (in days) for Laparoscopic Ovarian Drilling, broken down by (a) inpatient, and (b) outpatient appointment. 2. The longest completed wait (in days) for Laparoscopic Ovarian Drilling, broken down by (a) inpatient, and (b) outpatient appointment. 3. The median ongoing wait (in days) for Laparoscopic Ovarian Drilling, broken down by (a) inpatient, and (b) outpatient appointment. 4. The longest ongoing wait (in days) for Laparoscopic Ovarian Drilling, broken down by (a) inpatient, and (b) outpatient appointment
Date of Response: 27/06/2025
View Response: 10173.pdf
Freedom of Information Request Reference: 10172
Date Received: 30/05/2025
Summary:
Can I request the following information for each calendar year from 2019 to 2025 (most recent): 1. The number of people misdiagnosed when they have had a heart attack, broken down by (a) men, and (b) women. 2. The median completed wait (in days) for correct diagnosis of a heart attack, broken down by (a) men, and (b) women. 3. The longest completed wait (in days) for correct diagnosis of a heart attack, broken down by (a) men, and (b) women. 4. The number of people misdiagnosed when they have had heart disease, broken down by (a) men, and (b) women. 5. The median completed wait (in days) for correct diagnosis of heart disease, broken down by (a) men, and (b) women. 6. The longest completed wait (in days) for correct diagnosis of heart disease, broken down by (a) men, and (b) women.
Date of Response: 04/07/2025
View Response: 10172.pdf
Freedom of Information Request Reference: 10171
Date Received: 30/05/2025
Summary:
Can I request the following information for each calendar year from 2019 to 2025 (most recent): 1. The median completed wait (in days) for Vaginoplasty surgery for patients who have Vaginal agenesis, broken down by (a) inpatient, and (b) outpatient appointment. 2. The longest completed wait (in days) for Vaginoplasty surgery for patients who have Vaginal agenesis, broken down by (a) inpatient, and (b) outpatient appointment. 3. The median ongoing wait (in days) for Vaginoplasty surgery for patients who have Vaginal agenesis, broken down by (a) inpatient, and (b) outpatient appointment. 4. The longest ongoing wait (in days) for Vaginoplasty surgery for patients who have Vaginal agenesis, broken down by (a) inpatient, and (b) outpatient appointment
Date of Response: 04/07/2025
View Response: 10171.pdf
Freedom of Information Request Reference: 10170
Date Received: 30/05/2025
Summary:
please provide the data for 2020/2021, 2021/22, 2022/23, 2023/24, 2024/2025 and 2025 to date. Please also provide the following data for the past 12 months : 1. Number of suicides in in-patient psychiatric units 2. Number of suicides per 10,000 in-patient psychiatric admissions 3. Number of suicides of children and young people under 18 in in-patient psychiatric units 4. Number of suicides per 10,000 children and young people under 18 admitted to in-patient psychiatric units 5. Number of suicides within 3 months of being discharged from an in-patient psychiatric unit 6. Number of suicides per 10,000 discharges from in-patient psychiatric units within 3 months of discharge 7. Number of suicides of children and young people under 18 per 10,000 discharges from in patient-psychiatric units within 3 months of discharge 8. Number of suicides of children and young people under 18 discharged from in patient psychiatric units within 3 months of discharge If less than 10,000 patients have been admitted or discharged in any of these categories, please provide the number as another proportion (e.g 1 in 10, 1 in 5436 etc etc).
Date of Response: 04/07/2025
View Response: 10170.pdf
Freedom of Information Request Reference: 10169
Date Received: 30/05/2025
Summary:
1) a/What ME-specific services were offered by the health board in 2023, 2024 and 2025 to date? b/What services were offered in the board area in each of those years, relating to fibromyalgia, chronic fatigue syndrome and similar illnesses? 2) a/How much has been spent on the provision of ME specific services by the health board in 2023, 2024 and 2025 to date? b/How much was spent by the health board in 2024 and 2025 to date in the board area relating to fibromyalgia, chronic fatigue syndrome and similar illnesses?
Date of Response: 08/07/2025
View Response: 10169.pdf
Freedom of Information Request Reference: 10168
Date Received: 30/05/2025
Summary:
I would be grateful if you could provide the following details regarding your early pregnancy unit (EPU) services: • Do you provide a nurse lead early pregnancy unit EPU within your gynaecology directorate? • if so, what agenda for change banding are the nurses who are carrying out these duties? • What formal training or qualifications have these nurses undertaken to support their role in delivering care within the EPU? • Our nurses within your EPU responsible for performing ultrasound scans? If so, what training or accreditation do they hold to support this practice? • Do the nurses working in the EPU also have dual roles that include responsibilities within the gynaecology outpatient department? • Do your gynaecology nurses within the gynaecology directorate consent patients for the medical management of miscarriage? If so, what age agenda for change banding are these nurses?
Date of Response: 04/07/2025
View Response: 10168.pdf
Freedom of Information Request Reference: 10167
Date Received: 29/05/2025
Summary:
1. How many patients were admitted to hospitals in your NHS health board with malnutrition annually in the last 10 years of available data? 2. How many of those patients were children under 18 years of age? 3. How many patients in Scotland were admitted to hospital in your NHS health board with each of the following diseases annually in the last 10 years of available data? Scurvy Rickets Cholera Tuberculosis Scarlet fever Whooping cough Typhoid Scabies 4. For each of those diseases, how many of the patients admitted to hospital were children under 18 years of age?
Date of Response: 26/06/2025
View Response: 10167.pdf
Freedom of Information Request Reference: 10166
Date Received: 29/05/2025
Summary:
•The total number of employees eligible for shared parental leave (SPL) in each of the past five calendar years (or financial years, if easier to report). •The number of employees who applied for, and the number of employees who were approved, shared parental leave in each of those years, along with the length of leave applied for and approved, broken down by: gender; pay band or grade (if possible) In the same period (broken down by year if possible), the number of employees who took: •Maternity leave •Paternity leave •Any internal policy documents or guidance issued to staff regarding shared parental leave entitlement, including any updates in the past five years. •Any surveys, evaluations, or assessments conducted internally on the take-up or impact of shared parental leave (including barriers to uptake). •Whether enhanced pay is offered during shared parental leave, and if so, how it compares to maternity and paternity leave packages.
Date of Response: 26/06/2025
View Response: 10166.pdf
Freedom of Information Request Reference: 10165
Date Received: 29/05/2025
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available? Name of medicine 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Elacestrant (Orserdu) 1.4 Fulvestrant (fulvestrant or Faslodex) 1.5 Inavolisib (Inaqovi) 1.6 Palbociclib (Ibrance) 1.7 Ribociclib (Kisqali) 1.8 Capivasertib (Truqap) 1.9 Talazoparib (Talzenna) 1.10 Olaparib (Lynparza) Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 2.1 Abemaciclib (Verzenios) 2.2 Ribociclib (Kisqali) 2.3 Olaparib (Lynparza) Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 3.1 Abemaciclib (Verzenios) 3.2 Ribociclib (Kisqali) Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available? Name of combination or monotherapy 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025? Type of breast cancer 5.1 All types of breast cancer 5.2 Locally advanced or metastatic breast cancer Q6. How many patients were treated in total with the following products in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available? Name of medicine 6.1 Pertuzumab (Perjeta) 6.2 Pertuzumab with Trastuzumab (Phesgo) 6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 6.4 Trastuzumab Deruxtecan (EnHertu) 6.5 Trastuzumab Emtansine (Kadcyla) 6.6 Tucatinib (Tukysa) 6.7 Neratinib (Nerlynx) Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available? Name of medicine 7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 7.2 Trastuzumab Deruxtecan (EnHertu) Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available? Treatment intent 8.1 Pertuzumab (Perjeta) 8.2 Pertuzumab with Trastuzumab (Phesgo) 8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) 8.4 Trastuzumab Emtansine (Kadcyla) Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available? Treatment intent 9.1 Pertuzumab (Perjeta) 9.2 Pertuzumab with Trastuzumab (Phesgo) 9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 9.4 Trastuzumab Emtansine (Kadcyla) Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available? Treatment intent 10.1 HER2+ve Breast Cancer 10.2 HER2-low Breast Cancer
Date of Response: 07/07/2025
View Response: 10165.pdf
Freedom of Information Request Reference: 10164
Date Received: 29/05/2025
Summary:
1. In the last 12 months, how many unique patients in your health board were treated with the following products: A) Curosurf B) Peyona
Date of Response: 26/06/2025
View Response: 10164.pdf
Freedom of Information Request Reference: 10163
Date Received: 29/05/2025
Summary:
In the last 12 months, how many unique patients have been treated for Insomnia (ICD-10 code G47.0) with the following products: 1). Zopiclone 2). Zolpidem 3). Any other Melatonin product
Date of Response: 20/06/2025
View Response: 10163.pdf
Freedom of Information Request Reference: 10162
Date Received: 28/05/2025
Summary:
The number of patients who received assistance with private prescriptions from GP practices within the NHS Lothian area over the past 12 months.
Date of Response: 25/06/2025
View Response: 10162.pdf
Freedom of Information Request Reference: 10160
Date Received: 28/05/2025
Summary:
1. The number of FTE employees who work in NHS Lothian’s internal legal team, including all lawyers, solicitors, etc. in a) Financial Year 2022/23, b) Financial Year 2023/24, and c) Financial Year 2024/25. 2. The total amount spent by NHS Lothian on internal legal services, including the salaries of employees in the legal team, expenses, etc. in a) Financial Year 2022/23, b) Financial Year 2023/24, and c) Financial Year 2024/25. 3. The total amount spent by NHS Lothian on external legal services in a) Financial Year 2022/23, b) Financial Year 2023/24, and c) Financial Year 2024/25. FY 2022/23 FY 2023/24 FY 2024/25 No. of FTE internal legal team employees Amount spent on internal legal services Amount spent on external legal services
Date of Response: 30/06/2025
View Response: 10160.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS